LEXARIA BIOSCIENCE CORP (LEXX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$4.17+2.46%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LEXX
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The primary goal of the Reverse Split is to increase the per Share market price of the Company’s Shares with the objective of regaining compliance with the NASDAQ Capital Market’s (“ Nasdaq ”) minimu…
Stated in a supplied disclosure. Management reported: “The primary goal of the Reverse Split is to increase the per Share market price of the Company’s Shares with the objective of regaining compliance with the NASDAQ Capital Market’s (“ Nasdaq ”) minimum $1.00 bid price per share requirement of Nasdaq Listing Rule 5550(a)(2) (the “ Minimum Price Rule ”).” ““The Reverse Split is a critical step towards our continued listing on Nasdaq,” stated Richard Christopher, CEO of Lexaria Bioscience Corp. “We have determined that it is prudent and extremely important that the Reverse Split is conducted sooner rather than later,” continued Mr. Christopher.”
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 51% of the time over the next year (vs 41% for the rest of the cohort, n=13498).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $5.9 million, prior to deducting placement agent fees and other offering expenses.
Stated in a supplied disclosure. Management reported: “The gross proceeds to the Company from the exercise of the warrants are expected to be approximately $5.9 million, prior to deducting placement agent fees and other offering expenses.” “"The potential proceeds from this transaction, in combination with the $2.6 million tax rebate that we recently received from the Australian Tax Office, may be utilized to fund our operations and research and development programs in 2027."”
About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the b…
Stated in a supplied disclosure. Management reported: “About Lexaria Bioscience Corp. & DehydraTECH DehydraTECH™ is Lexaria's patented drug delivery formulation and processing platform technology which improves the way a wide variety of drugs enter the bloodstream, always through oral delivery.” “DehydraTECH has repeatedly evidenced the ability to increase bio-absorption, reduce side-effects, and deliver some drugs more effectively across the blood brain barrier.”
Over the trailing year it converted 0.97x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, real (inflation-adjusted) rates, the US dollar, long-term interest rates, Fed net liquidity (low R² over the window).
14 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 46% of the time over the next year (vs 44% for the rest of the cohort, n=13229).
Not investment advice. As of 2026-11-05.